The mission of the collaborative project between ASAKE Biotechnology, LLC and Ohio University researchers is to provide a lead compound in the development of a novel therapeutic that will aid patients with Type 1 diabetes (T1D) in enhancing insulin content and secretion while preventing cell death, providing the best combination of protection and insulin secretion to date.
ASAKE Biotechnology, LLC, through a licensing agreement with Ohio University researchers, is developing the first lead compound, MSB-3, designed to treat patients with Type 1 diabetes (T1D) in two significant and novel ways:
1. Reducing or preventing cell death that normally occurs with T1D, leading to decrease blood glucose levels and possibly slowing or halting disease progression without the need for additional insulin treatment.
2. Enhancing insulin content and secretion making it unnecessary for patients with T1D to rely on traditional injectable insulin therapy.
Over 1.9 million Americans (over 9 million people globally) suffer from T1D, an autoimmune disorder in which a body's immune system destroys a majority of insulin-producing pancreatic beta cells. Traditional injectable insulin therapy can result in a patient's risk of becoming immunocompromised and insulin intolerant. MSB-3, however, is showing promising results in stabilizing blood glucose and increasing pancreatic beta cells' insulin production without the risk of a patient becoming immunocompromised. The first lead compound to showcase these results, MSB-3 is being further studied and targeted with the goal of preparing it for clinical trials and eventual drug development.